SUNNYVALE, Calif., Feb. 1, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the second quarter of fiscal 2023 ended December 31, 2022.
Second Quarter Fiscal 2023 Summary
Other Recent Operational Highlights
"We have delivered another strong quarter of performance in Q2 showcasing the growing customer demand for our precision radiotherapy solutions and the excellent operational execution by the Accuray team amidst challenging macroeconomic conditions," said Suzanne Winter, Chief Executive Officer. "Our teams remain focused on advancing our innovation driven growth agenda so that we can deliver on our promise to improve the outcome and quality of life of patients diagnosed with cancer or neurological disease."
Fiscal Second Quarter Results
Total net revenue in the second quarter of fiscal 2023 was $114.8 million, compared to $116.3 million in the prior fiscal year second quarter. Product revenue in the second quarter of fiscal 2023 was $63.3 million, compared to $60.7 million in the prior fiscal year second quarter, while service revenue for the second quarter of fiscal 2023 was $51.5 million, compared to $55.6 million in the prior fiscal year second quarter.
Total gross profit in the second quarter of fiscal 2023 was $43.0 million, or 37.4 percent of total net revenue, compared to total gross profit of $42.6 million, or 36.7 percent of total net revenue, in the prior fiscal year second quarter.
Operating expenses in the second quarter of fiscal 2023 were $40.3 million, including non-recurring charges of $1.9 million for restructuring charges and $0.5 million of ERP and ERP related expenditures, compared to $38.6 million in the prior fiscal year second quarter. Excluding these non-recurring charges, total operating expenses were down 2.0 percent compared to the same period in the prior fiscal year.
Net loss in the second quarter of fiscal 2023 was $1.9 million, or $0.02 per share, compared to net income of $0.2 million, or $0.00 per share, in the prior fiscal year second quarter. Adjusted EBITDA in the second quarter of fiscal 2023 was $8.5 million, compared to $6.8 million in the prior fiscal year second quarter.
Gross product orders in the second quarter of fiscal 2023 totaled $79.0 million compared to $85.4 million in the prior fiscal year second quarter. Order backlog as of December 31, 2022 was $515.2 million, approximately 11.4% percent lower than at the end of the prior fiscal year second quarter. There were no order cancellations in the quarter and $41.4 million in orders aged out in the quarter as they were more than 30 months in age.
Cash, cash equivalents, and short-term restricted cash were $67.9 million as of December 31, 2022, a decrease of $21.0 million from June 30, 2022.
Fiscal Six Months Results
Total net revenue in the six months ended December 31, 2022 was $211.3 million, compared to $223.7 million in the same prior fiscal year period. Product revenue for the six months ended December 31, 2022 was $107.9 million, compared to $113.5 million in the same prior fiscal year period, while service revenue totaled $103.4 million, compared to $110.2 million in the same prior fiscal year period.
Total gross profit in the six months ended December 31, 2022 was $77.6 million, or 36.7 percent of total net revenue, compared to total gross profit of $82.2 million, or 36.7 percent of total net revenue in the same prior fiscal year period.
Operating expenses in the six months ended December 31, 2022 were $77.0 million, including non-recurring charges of $1.9 million for restructuring charges and $1.1 million of ERP and ERP related expenditures, compared to $75.8 million in the same prior fiscal year period. Excluding these non-recurring charges, total operating expenses were down 2.3 percent compared to the same period in prior fiscal year.
Net loss in the six months ended December 31, 2022 was $7.3 million, or $0.08 per share, compared to a net loss of $0.8 million, or $0.01 per share, in the same prior fiscal year period. Adjusted EBITDA for the six months ended December 31, 2022, was $10.4 million, compared to $12.2 million in the same prior fiscal year period.
Gross product orders in the six months ended December 31, 2022 totaled $148.9 million, compared to $155.4 million in the same prior fiscal year period. Order backlog as of December 31, 2022 was $515.2 million, approximately 11.4% percent lower than at the end of same period in the prior fiscal year period.
Fiscal Year 2023 Financial Guidance
Accuray's financial guidance is based on current expectations. The following statements are forward-looking and actual results could differ materially depending on market conditions, the impact of the current global economic environment and the Covid-19 pandemic, supply chain disruption, and the factors set forth under "Safe Harbor Statement" below.
The company is reaffirming guidance for fiscal year 2023 as follows:
Guidance for non-GAAP financial measures excludes depreciation and amortization, stock-based compensation, interest expense, provision for income taxes, restructuring charges and ERP and ERP related expenditures. For more information regarding the non-GAAP financial measures discussed in this press release, please see "Use of Non-GAAP Financial Measures" below.
Conference Call Information
Accuray will host a conference call beginning at 1:30 p.m. PT/4:30 p.m. ET today to discuss results for the second quarter of fiscal 2023 as well as recent corporate developments. Conference call dial-in information is as follows:
Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Investor Relations section of Accuray's website, www.accuray.com. There will be a slide presentation accompanying today's event which can also be accessed on the company's Investor Relations page at www.accuray.com.
In addition, a taped replay of the conference call will be available beginning approximately one hour after the call's conclusion and will be available for seven days. The replay number is (877) 344-7529 (USA), or (412) 317-0088 (International), Conference ID: 6435845. An archived webcast will also be available on Accuray's website until Accuray announces its results for the third quarter of fiscal 2023.
Use of Non-GAAP Financial Measures
Accuray reports its financial results in accordance with generally accepted accounting principles in the United States (GAAP) and the rules of the SEC. To supplement its financial statements prepared and presented in accordance with GAAP, Accuray uses certain non-GAAP financial measures, such as adjusted EBITDA, gross orders on a constant currency basis and net revenue on a constant currency basis.
Accuray has supplemented its GAAP net income (loss) with a non-GAAP measure of adjusted earnings before interest, taxes, depreciation, amortization and stock-based compensation ("adjusted EBITDA"). The calculation of adjusted EBITDA also excludes certain non-recurring, irregular and one-time items, including restructuring charges and ERP and ERP related expenditures. Management believes that this non-GAAP financial measure provides useful supplemental information to management and investors regarding the performance of the company and facilitates a meaningful comparison of results for current periods with previous operating results. A reconciliation of GAAP net income (loss) (the most directly comparable GAAP measure) to non-GAAP adjusted EBITDA is provided in the schedules below.
Accuray has also reported certain operating results on a constant currency basis in order to facilitate period-to-period comparisons of its results without regard to the impact of foreign currency exchange rate fluctuations. Management believes disclosure of non-GAAP constant currency results is helpful to investors because it facilitates period-to-period comparisons of the company's results by increasing the transparency of the underlying performance by excluding the impact of foreign currency exchange rate fluctuations. The GAAP measure most directly comparable to net revenue on a constant currency basis is revenue. Accuray calculates the constant currency amounts by translating local currency amounts in the current period using the same foreign translation rate used in the prior period being compared against rather than the actual exchange rate in effect during the current period.
There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may not be directly comparable to similarly titled measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for comparable GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the company's consolidated financial statements prepared in accordance with GAAP.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Sunnyvale, California, with facilities worldwide.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the company's future results of operations, including expectations regarding: total revenue and adjusted EBITDA; the effect of the global economic environment and the COVID-19 pandemic on the company and the market in general, including with respect to the company's ability to navigate supply chain, logistics, macroeconomic, and foreign exchange challenges; delivering on the company's growth agenda and executing on strategic partnerships; creating long term value for customers, patients, employees, and shareholders; expectations regarding commercial strategy and execution as well as growth opportunities; the company's order and revenue growth and ability to gain market share; expectations regarding the market in China as well as with respect to the company's China joint venture and other strategic partnerships, including its ability to create solutions that differentiate Accuray from other companies and provide value for patients, providers and shareholders; the company's product pipeline, innovations and developments, including those developed with strategic partners, the company's ability to drive above-market revenue growth in the radiation therapy and services market; and the company's ability to deliver on its promise to improve the outcome and quality of life of patients diagnosed with cancer or neurological disease. These forward-looking statements involve risks and uncertainties. If any of these risk or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results express or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the effect of the global macroeconomic environment, including foreign exchange, and the COVID-19 pandemic on the operations of the company and those of its customers and suppliers; disruptions to our supply chain, including increased logistics costs; the company's ability to achieve widespread market acceptance of its products; the company's ability to realize the expected benefits of the China joint venture and other partnerships; risks inherent in international operations; the company's ability to maintain or increase its gross margins on product sales and services; delays in regulatory approvals or the development or release of new offerings; the company's ability to meet the covenants under its credit facilities; the company's ability to convert backlog to revenue; and such other risks identified under the heading "Risk Factors" in the company's Annual Report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on November 3, 2022 and as updated periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Aman Patel, CFA | Beth Kaplan |
Investor Relations, ICR-Westwicke | Public Relations Director, Accuray |
+1 (443) 450-4191 | +1 (408) 789-4426 |
This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
Financial Tables to Follow
Accuray Incorporated | ||||||||||||||||
Condensed Consolidated Statements of Operations | ||||||||||||||||
(in thousands, except per share data) | ||||||||||||||||
(Unaudited) | ||||||||||||||||
Three Months Ended | Six Months Ended | |||||||||||||||
2022 | 2021 | 2022 | 2021 | |||||||||||||
Net revenue: | ||||||||||||||||
Products | $ | 63,269 | $ | 60,721 | $ | 107,892 | $ | 113,480 | ||||||||
Services | 51,491 | 55,554 | 103,361 | 110,237 | ||||||||||||
Total net revenue | 114,760 | 116,275 | 211,253 | 223,717 | ||||||||||||
Cost of revenue: | ||||||||||||||||
Cost of products | 39,248 | 35,520 | 68,098 | 67,029 | ||||||||||||
Cost of services | 32,545 | 38,128 | 65,591 | 74,537 | ||||||||||||
Total cost of revenue | 71,793 | 73,648 | 133,689 | 141,566 | ||||||||||||
Gross profit | 42,967 | 42,627 | 77,564 | 82,151 | ||||||||||||
Operating expenses: | ||||||||||||||||
Research and development | 14,641 | 14,697 | 28,733 | 29,079 | ||||||||||||
Selling and marketing | 13,586 | 13,233 | 24,381 | 24,504 | ||||||||||||
General and administrative | 12,035 | 10,716 | 23,927 | 22,176 | ||||||||||||
Total operating expenses | 40,262 | 38,646 | 77,041 | 75,759 | ||||||||||||
Income from operations | 2,705 | 3,981 | 523 | 6,392 | ||||||||||||
Loss on equity method investment, net | (699) | (832) | (1,067) | (1,172) | ||||||||||||
Other expense, net | (2,831) | (2,490) | (5,389) | (5,158) | ||||||||||||
Income (loss) before provision for income taxes | (825) | 659 | (5,933) | 62 | ||||||||||||
Provision for income taxes | 1,049 | 480 | 1,390 | 911 | ||||||||||||
Net income (loss) | $ | (1,874) | $ | 179 | $ | (7,323) | $ | (849) | ||||||||
Net income (loss) per share - basic | $ | (0.02) | $ | 0.00 | $ | (0.08) | $ | (0.01) | ||||||||
Net income (loss) per share - diluted | $ | (0.02) | $ | 0.00 | $ | (0.08) | $ | (0.01) | ||||||||
Weighted average common shares used in | ||||||||||||||||
Basic | 94,567 | 91,761 | 94,048 | 91,299 | ||||||||||||
Diluted | 94,567 | 93,932 | 94,048 | 91,299 | ||||||||||||
Accuray Incorporated | ||||||||
Condensed Consolidated Balance Sheets | ||||||||
(in thousands) | ||||||||
(Unaudited) | ||||||||
December 31, | June 30, | |||||||
2022 | 2022 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 67,729 | $ | 88,737 | ||||
Restricted cash | 189 | 204 | ||||||
Accounts receivable, net | 89,187 | 94,442 | ||||||
Inventories | 155,665 | 142,254 | ||||||
Prepaid expenses and other current assets | 23,536 | 23,794 | ||||||
Deferred cost of revenue | 642 | 1,459 | ||||||
Total current assets | 336,948 | 350,890 | ||||||
Property and equipment, net | 11,155 | 12,685 | ||||||
Investment in joint venture | 12,276 | 13,879 | ||||||
Operating lease right-of-use assets, net | 25,334 | 16,798 | ||||||
Goodwill | 57,776 | 57,840 | ||||||
Intangible assets, net | 268 | 250 | ||||||
Long-term restricted cash | 1,293 | 1,213 | ||||||
Other assets | 23,719 | 19,294 | ||||||
Total assets | $ | 468,769 | $ | 472,849 | ||||
Liabilities and equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 33,861 | $ | 31,337 | ||||
Accrued compensation | 20,099 | 29,441 | ||||||
Operating lease liabilities, current | 4,913 | 8,567 | ||||||
Other accrued liabilities | 30,301 | 30,285 | ||||||
Customer advances | 17,169 | 25,290 | ||||||
Deferred revenue | 72,675 | 75,375 | ||||||
Short-term debt | 5,702 | 8,563 | ||||||
Total current liabilities | 184,720 | 208,858 | ||||||
Operating lease liabilities, non-current | 22,664 | 10,453 | ||||||
Long-term other liabilities | 5,181 | 3,748 | ||||||
Deferred revenue, non-current | 30,357 | 24,694 | ||||||
Long-term debt | 174,102 | 171,907 | ||||||
Total liabilities | 417,024 | 419,660 | ||||||
Equity: | ||||||||
Common stock | 95 | 94 | ||||||
Additional paid-in capital | 550,288 | 543,211 | ||||||
Accumulated other comprehensive income | 1,541 | 2,406 | ||||||
Accumulated deficit | (500,179) | (492,522) | ||||||
Total equity | 51,745 | 53,189 | ||||||
Total liabilities and equity | $ | 468,769 | $ | 472,849 | ||||
Accuray Incorporated | ||||||||||||||||
Summary of Orders and Backlog | ||||||||||||||||
(in thousands, except book to bill ratio) | ||||||||||||||||
(Unaudited) | ||||||||||||||||
Three Months Ended | Six Months Ended | |||||||||||||||
2022 | 2021 | 2022 | 2021 | |||||||||||||
Gross Orders | $ | 79,035 | $ | 85,381 | $ | 148,883 | $ | 155,365 | ||||||||
Net Orders | 40,869 | 40,183 | 60,439 | 80,946 | ||||||||||||
Order Backlog | 515,236 | 581,267 | 515,236 | 581,267 | ||||||||||||
Book to bill ratio (a) | 1.2 | 1.4 | 1.4 | 1.4 | ||||||||||||
(a) Book to bill ratio is defined as gross orders for the period divided by product revenue for the period |
Accuray Incorporated | ||||||||||||||||
Reconciliation of GAAP Net Income (Loss) to Adjusted Earnings Before Interest, Taxes, Depreciation, | ||||||||||||||||
Amortization and Stock-Based Compensation (Adjusted EBITDA) | ||||||||||||||||
(in thousands) | ||||||||||||||||
(Unaudited) | ||||||||||||||||
Three Months Ended | Six Months Ended | |||||||||||||||
2022 | 2021 | 2022 | 2021 | |||||||||||||
GAAP net income (loss) | $ | (1,874) | $ | 179 | $ | (7,323) | $ | (849) | ||||||||
Depreciation and amortization (a) | 1,151 | 1,422 | 2,327 | 2,841 | ||||||||||||
Stock-based compensation | 3,126 | 2,695 | 6,042 | 5,211 | ||||||||||||
Interest expense, net (b) | 2,642 | 2,070 | 4,898 | 4,106 | ||||||||||||
Provision for income taxes | 1,049 | 480 | 1,390 | 911 | ||||||||||||
Restructuring charges | 1,938 | — | 1,938 | — | ||||||||||||
ERP and ERP related expenditures | 466 | — | 1,121 | — | ||||||||||||
Adjusted EBITDA | $ | 8,498 | $ | 6,846 | $ | 10,393 | $ | 12,220 | ||||||||
(a) consists of depreciation, primarily on property and equipment as well as amortization of intangibles. |
(b) consists primarily of interest expense associated with outstanding debt. |
Accuray Incorporated | ||||||||
Forward-Looking Guidance | ||||||||
Reconciliation of Projected Net Income (Loss) to Projected Adjusted Earnings Before Interest, Taxes, Depreciation, | ||||||||
(in thousands) | ||||||||
(Unaudited) | ||||||||
Twelve Months Ending | ||||||||
From | To | |||||||
GAAP net loss | $ | (5,500) | $ | (1,500) | ||||
Depreciation and amortization (a) | 6,300 | 6,300 | ||||||
Stock-based compensation | 11,600 | 11,600 | ||||||
Interest expense, net (b) | 8,000 | 8,000 | ||||||
Provision for income taxes | 2,000 | 2,000 | ||||||
Restructuring charges | 2,000 | 2,000 | ||||||
ERP and ERP related expenditures | 1,600 | 1,600 | ||||||
Adjusted EBITDA | $ | 26,000 | $ | 30,000 | ||||
(a) consists of depreciation, primarily on property and equipment as well as amortization of intangibles. |
(b) consists primarily of interest expense associated with outstanding debt. |
| Last Trade: | US$2.15 |
| Daily Change: | 0.06 2.87 |
| Daily Volume: | 770,303 |
| Market Cap: | US$213.370M |
November 06, 2024 September 10, 2024 August 27, 2024 August 14, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
